Targets › BRAF
26 programs from 18 companies in 126 trials: 79 Phase 2, 31 Phase 1, 12 Phase 3, 4 Phase 4; Oncology, Hematology, Gastroenterology; next expected readout Nov 2026.
Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway. (UniProt, P15056)
Open in Phaseline: the race on BRAF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Dabrafenib Serine/threonine-protein kinase B-raf inhibitor | BRAF | Phase 4 | Diffuse Astrocytoma; Melanoma; Differentiated Thyroid Cancer (DTC); Advanced Thyroid Cancer Patients Who Received Target Therapy … | Nov 2026 |
| Pfizer | Encorafenib Serine/threonine-protein kinase B-raf inhibitor | BRAF | Phase 4 | Solid Tumors; Melanoma; Neoplasms; Metastatic Colorectal Cancer … | Jan 2027 |
| Pierre Fabre Medicament | Encorafenib Serine/threonine-protein kinase B-raf inhibitor | BRAF | Phase 3 | Melanoma; Non-Small Cell Lung Cancer | Dec 2026 |
| Erasca | Naporafenib B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor | RAF1, BRAF | Phase 3 | Advanced or Metastatic NRAS-mutant Melanoma; Advanced or Metastatic Solid Tumors | Dec 2026 |
| National Cancer Institute (NCI) | Dabrafenib Mesylate Serine/threonine-protein kinase B-raf inhibitor | BRAF | Phase 3 | Clinical Stage III Cutaneous Melanoma AJCC v8; Advanced Lymphoma; Stage III Cutaneous Melanoma AJCC v7; Anaplastic Astrocytoma … | Dec 2026 |
| Shanghai Kechow Pharma | Vemurafenib Serine/threonine-protein kinase B-raf inhibitor | BRAF | Phase 3 | Colorectal Cancer Metastatic | Dec 2026 |
| Day One Biopharmaceuticals | Tovorafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 3 | Low-grade Glioma; Craniopharyngioma, Child; Recurrent Langerhans Cell Histiocytosis; Hairy Cell Leukemia | May 2027 |
| Roche | Sorafenib Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | RAF1, PDGFRB, KIT, FLT3, BRAF | Phase 3 | Unresectable Hepatocellular Carcinoma; AML (Acute Myeloid Leukemia); Locally Advanced Thyroid Gland Carcinoma; Hepatocellular Carcinoma … | – |
| Roche | Vemurafenib Serine/threonine-protein kinase B-raf inhibitor | BRAF | Phase 2 | Non-small Cell Lung Cancer; Thyroid Gland Follicular Carcinoma; Colorectal Carcinoma; Hairy Cell Leukemia … | Nov 2026 |
| Nanfang Hospital, Southern Medical University | Donafenib multi-targeted tyrosine kinase inhibitor | BRAF, FLT3, RET | Phase 2 | Unresectable Hepatocellular Carcinoma | Dec 2026 |
| Fudan University | Vermofenib BRAF V600E inhibitor | BRAF | Phase 2 | Colorectal Cancer Metastatic | Dec 2026 |
| Novartis | Naporafenib (LXH254) B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor | RAF1, BRAF | Phase 2 | Melanoma; EGFR-mutant Non-small Cell Lung Cancer | Feb 2027 |
| National Cancer Institute (NCI) | Sorafenib Tosylate Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | RAF1, PDGFRB, KIT, FLT3, BRAF | Phase 2 | Gastrointestinal Stromal Tumor; Acute Myeloid Leukemia; Advanced Malignant Solid Neoplasm | Mar 2027 |
| Shanghai Changzheng Hospital | Chidamide RAF inhibitor | BRAF | Phase 2 | Advanced Colorectal Cancer in the Third-line Treatment and Beyond | Apr 2027 |
| Fore Biotherapeutics | plixorafenib Serine/threonine-protein kinase B-raf inhibitor | BRAF | Phase 2 | Cancer Harboring BRAF Alterations | Dec 2027 |
| Hanmi Pharmaceutical Company | Belvarafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 2 | Advanced or Metastatic Melanoma | Sep 2029 |
| Ruijin Hospital | Giritinib RAF inhibitor | BRAF | Phase 2 | AML | Mar 2030 |
| Yu Wang | Donafenib Multikinase inhibitor targeting BRAF, VEGFR, and FLT3 | BRAF, VEGFR, FLT3 | Phase 2 | Thyroid Cancer | – |
| Roche | Belvarafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 1 | Melanoma; Primary Brain Tumor | Dec 2026 |
| Haisco Pharmaceutical Group | HSK42360 BRAF V600 inhibitor | BRAF | Phase 1 | Solid Tumors; Malignant Brain Tumors | Jul 2027 |
| Pfizer | PF-07799544 BRAF inhibitor | BRAF | Phase 1 | Melanoma | Aug 2027 |
| Pfizer | PF-07799933 BRAF inhibitor | BRAF | Phase 1 | Melanoma | Aug 2027 |
| Institut de Recherches Internationales Servier | S241656 RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) | BRAF, CRAF, KRAS, NRAS | Phase 1 | Non-small Cell Lung Cancer | Jun 2028 |
| Pierre Fabre Medicament | KIN-2787 BRAF inhibitor | BRAF | Phase 1 | Solid Tumor, Adult | Nov 2028 |
| Haisco Pharmaceutical Group | HSK42360-Na BRAF V600 inhibitor | BRAF | Phase 1 | Solid Tumors (Phase 1); Metastatic Colorectal Cancer (CRC) | Dec 2028 |
| Ipsen | Tovorafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 1 | Low-grade Glioma | Jul 2030 |
Melanoma (12) Thyroid Cancer (4) Hairy Cell Leukemia (4) Hepatocellular Carcinoma (4) Neoplasms (3) Solid Tumors (3) Colorectal Cancer (3) Low-grade Glioma (3) Advanced Colorectal Cancer in the Third-line Treatment and Beyond (3) Metastatic Malignant Neoplasm in the Brain (2) Haematological Malignancy (2) Colorectal Cancer Metastatic (2)
small molecule (15), mixed (6), antibody (4), protein or peptide (1)
Roche (3) Pfizer (3) Pierre Fabre Medicament (2) Novartis (2) Haisco Pharmaceutical Group (2) National Cancer Institute (NCI) (2) Erasca (1) Fore Biotherapeutics (1) Fudan University (1) Ruijin Hospital (1) Yu Wang (1) Shanghai Kechow Pharma (1) Day One Biopharmaceuticals (1) Nanfang Hospital, Southern Medical University (1) Ipsen (1) Institut de Recherches Internationales Servier (1) Hanmi Pharmaceutical Company (1) Shanghai Changzheng Hospital (1)
RAF1 (8) FLT3 (4) ARAF (4) PDGFRB (2) KIT (2) VEGFR (1) RET (1) CRAF (1) KRAS (1) NRAS (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.